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Oral Presentations S231GVHD in recipients of UCBT, we extended our analysis of patients
in our earlier study to determine rates of GVHDpersistence, contin-
ued immunosuppressive therapy, and survival at 1, 2 and 3 years
post-UCBT. A total of 81 patients were enrolled on our local,
IRB-approved UCBT trial between January 1996 and July 2007. Se-
venty-nine percent (54/68) of patients had malignant diagnoses and
21% (14/68) had nonmalignant disorders. Thirteen patients were ex-
cluded from analysis due to death prior to engraftment (7), graft re-
jection (4), or re-transplant during the follow-up period (2). Median
age of evaluable patients was 7.2 years (Range, 0.3-24.4years).
Among the 68 evaluable patients, 40 (59%) developed GVHD fol-
lowing UCBT. Based on Seattle criteria, 36 patients (53%) experi-
enced Grade I-IV acute GVHD with 17 (25%) classified as Grade
III-IV. Chronic GVH occurred in 21 of 58 patients (36%) surviving
beyond Day 100, including 4 with de novo chronic GVH. Chronic
GVHD was limited in 2 patients and extensive in 19. No new onset
chronic GVH was seen beyond 1 year post-transplant. In patients
with prior GVHD, persistent GVHD activity was present in 28%
(7/25), 14% (3/22) and 0% (0/20) of patients at 1, 2 and 3 years
post-UCBT. Among those with prior GVHD, 68% (17/25), 41%
(9/22) and 10% (2/20) of patients remained on one or more systemic
immunosuppressive medications at 1, 2 and 3 years post-UCBT.
Survival of patients with prior GVHD was 63% (25/40), 55% (22/
40) and 50% (20/40) at 1, 2 and 3 years post-UCBT. We conclude
that the course of GVHD following UCBT is both more manage-
able, i.e.-not associated with increased mortality, and resolves in
nearly all patients by 3 years post-UCBT allowing discontinuation
of immunosuppressive therapy. These features of GVHD in
UCBT appear to differentiate this product from adult unrelated
stem cell sources.
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ENCOURAGING RESULTS WITH THE USE OF FLUDARABINE BASED CON-
DITIONING REGIMENS IN CHILDRENWITH ACQUIRED AND CONGENITAL
BONE MARROW FAILURE SYNDROMES (BMFS)
George, B., Mathews, V., Ahmed, R., Abraham, A., Srivastava, A. Chris-
tian Medical College, Vellore, Tamilnadu, India
Between July 1999 and June 2011, sixty children (39 male and 21
female) with acquired and congenital BMFS underwent HLA iden-
tical stem cell transplantation (HSCT) using a fludarabine based
protocol. This included 39 patients with acquired aplastic anemia
(AA), 19 with Fanconi’s anemia (FA) and 2 with dyskeratosis conge-
nita (DKC). Three patients with FA hadmyelodysplastic syndromes.
The conditioning protocol used for AAwas Fludarabine (180mg/m2
over 6 days), Cyclophosphamide (120mg/kg over 2 days) + Anti- thy-
mocyte globulin (40mg/kg over 4 days). In patients with FA and
DKC, the dose of cyclophosphamide was reduced to 20 mg/kg and
in 3 patients with MDS, cyclophosphamide was replaced by busul-
fan. Cyclosporine with mini methotrexate was used for GVHD pro-
phylaxis. Graft source included peripheral blood stem cells (44) or
G-CSF stimulated bone marrow (16).
Fifty six patients engrafted (93.3%) while 2 patients with AA had
primary graft failure and 2 expired\2 weeks post HSCT. The me-
dian time to neutrophil engraftment was 14 days (range: 9 – 29) while
median time to platelet engraftment was 11 days (range: 7 – 31). Four
patients with FA/DKC and 2 patients with AA had secondary graft
rejection. Incidence of acute GVHD was 20% in children with AA
while it was 28.5% in children with congenital BFMS. Chronic
GVHD was seen in 33.3% of AA and 40% of children with congen-
ital BFMS. Three childrenwith AA and 3 with FA/DKChave under-
gone a second transplant using the same donor. The 2 year overall
survival is 83.3%with a survival of 87.1% in children with idiopathic
AA and 76.2% in children with congenital BFMS.
Fludarabine based protocols are associated with excellent survival
in children with acquired and congenital bone marrow failure syn-
dromes.
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OUTCOME OF MIXED CHIMERISM IN CHILDREN UNDERGOING ALLOGE-
NEIC STEM CELL TRANSPLANT (HSCT) FOR THALASSEMIA MAJOR
George, B., Mathews, V., Sindhuvi, E., Jain, S., Ahmed, R.,
Abraham, A., Srivastava, A. Christian Medical College, Vellore, Tamil-
nadu, IndiaA number of patients develop mixed chimerism following HSCT
for thalassemia despite the use of myeloablative chemotherapy. This
study analysed the outcome of mixed chimerism in children who un-
derwent allogeneic HSCT for thalassemia.
Between Jan 1995 to June 2011, 265 children underwent HLA
identical allogeneic HSCT for thalassemia using sibling or family
donors where chimerism data was available. Patients had chimerism
analysis performed using VNTRs performed initially at day 30 and
then as required. Mixed chimerism (MC) was graded as per Nesci
et al into level I (host cells\10%), level II (host cells 10-30%) or
level III (. 30%). Complete chimerism was the presence of\5%
host cells. Therapeutic interventions included taper of immunosup-
pression or use of donor lymphocyte infusion.
Seventy patients (26.4%) developed mixed chimerism either at
Day 30 or during subsequent follow up. Thirty five patients (50%)
had level I, 14 (20%) had level II and 8 (11.4%) had level III MC
while 13 (18.6%) had complete chimerism (CC) on day 30 but sub-
sequently developed MC. Of the 35 patients with Level 1 MC, 14
achieved CC while 17 (70%) had stable mixed chimerism (3 re-
mained at level 1; 4 progressed to level II or III) and 4 (11.4%) re-
jected. Of the 14 with Level 1I MC, 2 (14.2%) achieved CC, 6
(42.8%) had stable mixed chimerism with transfusion independence
and 6 (42.8%) rejected. Among 8 patients with level III chimerism, 6
(75%) rejected while 1 achieved CC after a DLI and 1 remained at
level III but remained transfusion independent. Thirteen patients
achieved CC by Day +30 but subsequently lost their chimerism - 2
dropped to level I, 5 to level II, 6 to level III. Of these, 11 (84.6%)
are either in CC or have stable mixed chimerism while 2 (15.4%)
had secondary rejection.
There is an increased risk of secondary rejection in patients with
level II and III MC at Day 30 following allogeneic HSCT for thal-
assemia. Newer strategies need to be adopted to reduce graft rejec-
tion in these patients.
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PATIENTS WITH EARLY INITIATION OF DLI FOR MIXED DONOR CHIME-
RISM WERE MORE LIKELY TO HAVE IMPROVEMENT IN DONOR CHIME-
RISM
Haines, H.L.1, Filipovich, A.H.2 1University of Alabama Birmingham,
Birmingham, AL; 2Cincinnati Children’s Hospital Medical Center, Cin-
cinnati, OH
Background: Increased use of reduced intensity conditioning regi-
mens in the pediatric setting mean more patients will require T
cell donor lymphocyte infusion (DLI) for mixed donor chimerism.
A retrospective review of 33 patients (age # 21 years) who received
DLI as primary cellular therapy for mixed chimerism from 2006 to
2010 was conducted.
Patients andmethods:Most patients underwent hematopoietic cell
transplant (HCT) for non-malignant disease after a preparative reg-
imen consisting of alemtuzumab, fludarabine andmelphalan. Indica-
tions for HCT were immune deficiency (29), Fanconi Anemia (1),
Hurler’s (1), Langerhans Cell Histiocytosis (1), and myelodysplasia
(1). Patients received DLI for mixed chimerism after reduction in
immune suppression was ineffective.
Results: Patients received a mean of 3.2 DLIs (range 1-12). Mean
first T cell dose was 2.6 X 106 cells/kg; mean total T cell dose was
5.8 X 107 cells/kg. Average donor chimerism prior to first DLI was
42%. Sixteen patients (48%) had increase from pre-DLI donor chi-
merism of $ 20% within eight weeks of DLI and were classified as
responders. Response was seen at a mean of 21 days after DLI (range
1-42) with peak donor chimerism seen at 51 days. Complete response
(peak donor chimerism of .99%) was seen in eleven patients. One
patient had graft versus host disease (GVHD) prior to DLI. Ten pa-
tients, all responders, developedGVHDafterDLI. GVHDwas gen-
erally mild with only two patients having $ grade 3.
When responders were compared with non-responders (Table 1)
there was no difference in donor chimerism prior to DLI therapy,
number of DLIs, or total and initial T cell doses. However, re-
sponders received their first DLI earlier after HCT, likely due to re-
sponders’ tendency toward earlier loss of donor chimerism after
HCT and shorter lag time between decreased donor chimerism
and first DLI. Response rates were higher for patients who received
DLI early after donor chimerism drop. Patients who received first
DLI # 50 days after loss of donor chimerism (N 5 17) had a 71%
response rate; patients who received DLI . 50 days (N 5 13) after
